EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieVergleichsstudieÄquivalenzstudie

Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma

Pei-Yu Huang, Xu-Yin Chen, Xi Ding, Ling Guo, Hao-Yuan Mo, Xiong Zou, Chong-Yang Duan, Li Ling, Rui You, Xin Yang, You-Ping Liu, Yu-Long Xie und 19 weitere

NEJM Evidence · 2025

DOI: 10.1056/evidoa2400214 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift NEJM Evidence, 2025. Verfasst von Pei-Yu Huang und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Rd, Guangzhou, China. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Cisplatin, Nasopharyngeal Neoplasms, Chemoradiotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cisplatin-based concurrent chemoradiotherapy (CCRT) is the mainstay treatment for locoregionally advanced nasopharyngeal carcinoma (LA-NPC), which usually leads to intolerable toxicities. We investigated whether or not induction chemotherapy (IC) plus intensity-modulated radiation therapy (IMRT) could replace CCRT. METHODS: This is an open-label, phase 3, noninferiority trial. Patients with stage T1-4N2-3 or T3-4N0-1 LA-NPC were randomly assigned (1:1) to receive gemcitabine (1000 mg/m2) and cisplatin (80 mg/m2) for two cycles followed by IMRT, or IMRT plus concomitant weekly cisplatin (40 mg/m2) for up to seven cycles. Two-year failure-free survival (FFS) was the primary end point, and noninferiority was confirmed by an upper limit of the 95% confidence interval (CI) for a hazard ratio of less than 2.12 (absolute margin of -10 percentage points). Secondary end points include overall survival, locoregional recurrence-free survival, distant metastasis-free survival, toxicity profile, and quality of life (QoL). RESULTS: We enrolled 124 patients in the IC group and 125 patients in the CCRT group. The median follow-up was 60 months. Two-year FFS was 90.2% for IC versus 86.3% for CCRT, with a hazard ratio of 0.636 (95% CI, 0.267 to 1.514) and an absolute difference of 3.9 percentage points (95% CI, -5.2 to 13.0). Compared with the CCRT group, fewer grade ≥3 adverse events occurred in the IC group (47.5% vs. 61.5%; P=0.029), including leukopenia, anemia, mucositis, nausea, and dysphagia. IC was associated with better QoL, including global health status, social and cognitive functioning, fatigue, nausea and vomiting, pain, appetite loss, and constipation. CONCLUSIONS: For 2-year FFS for LA-NPC, gemcitabine and cisplatin IC plus IMRT alone was noninferior to CCRT. (Funded by Key-Area Research and Development of Guangdong Province and others.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaCisplatinNasopharyngeal NeoplasmsChemoradiotherapyInduction ChemotherapyRadiotherapy, Intensity-ModulatedAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAdultGemcitabineDeoxycytidineAgedQuality of Life

Substanzen

CisplatinGemcitabineDeoxycytidine

Autor:innen und Institutionen

  • Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Rd, Guangzhou, China.
  • State Key Laboratory of Oncology in South China, Guangzhou, P. R. China.
  • Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China; Sun Yat-sen University Cancer Center, Guangzhou,…
  • Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China.
  • Department of Medical Statistics, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Sun Yat-sen Center for Migrant Health Policy, Sun Yat-sen University, Guangzhou, Guangdong, China.

Zitieren

APA

Huang, P. Y., Chen, X. Y., Ding, X., Guo, L., Mo, H. Y., Zou, X., Duan, C. Y., Ling, L., You, R., Yang, X., Liu, Y. P., Xie, Y. L., Zhang, Y. N., Cao, J. Y., Liu, S. H., Wang, Z. M., Yang, Q., Lin, C., Chen, S. Y., …, & Chen, M. Y. (2025). Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma. NEJM Evidence. https://doi.org/10.1056/evidoa2400214

Vancouver

Huang PY, Chen XY, Ding X, Guo L, Mo HY, Zou X, et al. Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma. NEJM Evidence. 2025. doi:10.1056/evidoa2400214

BibTeX
@article{Huang2025,
  author = {Huang, Pei-Yu and Chen, Xu-Yin and Ding, Xi and Guo, Ling and Mo, Hao-Yuan and Zou, Xiong and Duan, Chong-Yang and Ling, Li and You, Rui and Yang, Xin and Liu, You-Ping and Xie, Yu-Long and Zhang, Yi-Nuan and Cao, Jing-Yu and Liu, Si-Han and Wang, Zi-Meng and Yang, Qi and Lin, Chao and Chen, Si-Yuan and Ouyang, Yan-Feng and Liu, Yong-Long and Wen, Kai and Duan, Xiao-Tong and Jiang, Rou and Liu, Rong-Zeng and Yu, Tao and Qiu, Fang and Hua, Yi-Jun and Cao, Ka-Jia and Luo, Dong-Hua and Chen, Ming-Yuan},
  title = {Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma},
  journal = {NEJM Evidence},
  year = {2025},
  doi = {10.1056/evidoa2400214}
}
Kostenlos starten →